Beijing Medical Reform pharmaceutical enterprises will go to the grassroots level with patients

Source: medical geography on April 25, 2017, the director of Beijing health and Family Planning Commission said that in the past year of reform and reform of medical separation, the number of outpatient and emergency treatment in tertiary hospitals decreased by 11.9% compared with the previous year, while that in secondary hospitals was basically the same The number of outpatient and emergency treatment in primary hospitals and primary medical and health institutions reached nearly 80 million, a net increase of more than 12 million, or 16.1% compared with the previous year The number of diagnosis and treatment in some community health service institutions increased by about 25-30% Some common diseases are gradually distributed to grass-roots institutions, which has reversed the decline or hesitation of grass-roots diagnosis and treatment in the past decade, and the temporary state of overcrowding in large hospitals has been alleviated According to the official data of Beijing health and Family Planning Commission, in 2016, the number of tertiary hospitals reached 125.255 million, and in 2017, 113.856 million More than 12 million people visited tertiary hospitals As soon as this data is published, it has attracted attention from all walks of life, and the industry has greatly affirmed the effect of Beijing's medical reform For many pharmaceutical enterprises, the effect of Beijing's medical reform in one year is undoubtedly a mobilization order, playing a rallying point for pharmaceutical enterprises to go to the grassroots level With such a large number of people shunted to the grassroots level, pharmaceutical companies can't help but pay attention to nearly 8 billion medical visits a year in China, with tertiary hospitals accounting for the majority More than 12 million people return to the grassroots level, which may not hurt the tertiary hospitals, but it cannot be ignored by pharmaceutical companies There are many customers in pharmaceutical enterprises, but patients are the final end customers of drug consumption, their flow will undoubtedly have an impact on pharmaceutical enterprises If the flow of patients is small, pharmaceutical companies can ignore or even ignore it; but if the flow of patients is large enough, pharmaceutical companies can not ignore it In particular, more than 12 million people have returned to the grass-roots level in Beijing's medical reform in a year Such a large volume change also means that the proportion of drug consumption in grass-roots medical institutions has increased Suppose a person consumes 100 yuan of drugs a year at a time, which is more than 1.2 billion in sales Such a large number of consumer customers are transferred to the grass-roots level It is estimated that no matter which drug company is indifferent to it! In this case, it means that the marketing of pharmaceutical enterprises at the grassroots level is becoming more and more important Only by taking the initiative to seize the market, can we have a place in the future competition The third level hospital and the grass-roots drug directory are open Pharmaceutical enterprises cannot ignore the importance of Beijing Medical Reform in the deployment of hierarchical diagnosis and treatment work There is a very important measure that pharmaceutical enterprises should also pay attention to It is to further clarify the functional positioning of medical institutions at all levels and loosen the original directory of basic drugs of primary medical institutions The drug catalogue of primary medical institutions is completely connected with that of tertiary hospitals This policy plays a very important role in promoting classified diagnosis and treatment: first, it is conducive to providing medication services for patients with chronic diseases at the grass-roots level Most of the chronic patients in stable period will choose to buy drugs at the grass-roots level It is not only convenient to purchase drugs, but also good for medical experience, let alone family doctors' signing service, which can purchase up to two months' dosage at a time; it breaks the artificial restrictions on the use of drugs, so that patients have the free choice to purchase drugs; it greatly affects the layout of pharmaceutical enterprises In particular, the original grass-roots drug companies do not pay enough attention No more attention will be paid to the marginalization of the grass-roots drug market in the future Pharmaceutical enterprises should understand the deep meaning of Beijing's medical reform exploration At present, the national medical reform has entered a deep-water period What's easy to change has been done All the bones left are hard to chew Hierarchical diagnosis and treatment has always been one of the core work of medical reform Although there are explorations in various regions, the effect is not so good At present, there is not a relatively successful hierarchical diagnosis and treatment mode As soon as the data of Beijing medical reform is released, the results are quite good, especially the effect of hierarchical diagnosis and treatment has achieved initial results In time, after further improvement, Beijing's medical reform, especially the hierarchical diagnosis and treatment model, is likely to be extended It is the political center of our country Whether its medical reform is successful or not has a benchmarking effect The data released this time, the effect of hierarchical diagnosis and treatment is very obvious In time, it is not impossible for this mode to be popularized everywhere If the drug companies do not have enough response to this change, they may be in a passive position in the grass-roots drug market in the future The message that has been sent out in Beijing's medical reform is undoubtedly a clarion call for drug companies to gather at the grassroots level Pharmaceutical enterprises should pay attention to the great changes in the drug sales market It is an indispensable work direction for the future development of pharmaceutical enterprises to go deep into the grass-roots level, take root in the grass-roots level and do a good job in the grass-roots level.